Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease (RUN-CD)
Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease in Conjunction With Long-term Outcome
Sponsor: Ced Service GmbH
Listed as NCT03108326, this observational or N/A phase trial focuses on Crohn Disease and remains ongoing. Sponsored by Ced Service GmbH, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
May 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — May 2023 [monthly]
Recruiting
-
Aug 2018 — Jan 2021 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Feb 2018 [monthly]
Not Yet Recruiting NA
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ced Service GmbH
For direct contact, visit the study record on ClinicalTrials.gov .